A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma

被引:75
作者
Druzgal, CH
Chen, Z
Yeh, NT
Thomas, GR
Ondrey, FG
Duffey, DC
Vilela, RJ
Ende, K
McCullagh, L
Rudy, SF
Muir, C
Herscher, LL
Morris, JC
Albert, PS
Van Waes, C
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA
[3] NIH, Radiat Oncol Sci Program, Bethesda, MD 20892 USA
[4] NIH, Ctr Canc Res, Metab Branch, Bethesda, MD 20892 USA
[5] NIH, Biometr Res Branch, Bethesda, MD 20892 USA
[6] NCI, NIH, Bethesda, MD 20892 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2005年 / 27卷 / 09期
关键词
squamous cell carcinoma; cytokines; interleukin-6; interleukin-8; vascular endothelial growth factor; growth regulated oncogene 1;
D O I
10.1002/hed.20246
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Head and neck squamous cell carcinomas (HNSCCs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. Pretreatment and posttreatment serum levels of cytokines and angioaenesis factors were evaluated as markers for outcome in patients with HNSCC. Methods, Baseline cytokine and factor levels of 29 patients with HNSCC were compared with those of 15 age-matched and sex-matched controls, and pretreatment and posttreatment levels of 22 of the patients eligible for treatment and followed for a median of 37 months were compared. Results. Mean serum concentrations of interleukin (IL)-6, IL-8, hepatocyte growth factor (HGF), vascular enclothelial growth factor (VEGF), and growth regulated oncogene 1 (GRO-1) were increased in patients with HNSCC, but elevation of these factors was not associated with clinical outcome. However, changes in first posttreatment serum cytokine levels were observed for many of the patients consistent with response, progression, and survival. Later increases in IL-6 or HGF were observed in patients who had a relapse and inflammatory or infectious complications. A relationship between the change in the pretreatment and first posttreatment cytokine measurement with survival was detected for HGF, IL-8, IL-6, and VEGF using a Cox-proportional hazards model (p =.004, p =.06, p =. 10, and p =.11). The association between longitudinal decreases in IL-6, L-8, VEGF, and HGF throughout the follow-up with survival was detected with a time-dependent Cox model (p =.01, .07, .08, and .05, respectively). Conclusions. Longitudinal changes in serum HGF, IL-6, IL-8, and VEGF were detected with treatment response, relapse, or complications in individual patients and were associated with survival, with HGF showing the strongest relationship with survival. HGF, IL-6, IL-8, and VEGF merit investigation as markers of response, survival, and recurrence in larger prospective studies. (c) 2005 Wiley Periodicals, Inc.
引用
收藏
页码:771 / 784
页数:14
相关论文
共 42 条
[1]  
Benoy Ina, 2002, Clin Breast Cancer, V2, P311, DOI 10.3816/CBC.2002.n.008
[2]   SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER [J].
BEREK, JS ;
CHUNG, C ;
KALDI, K ;
WATSON, JM ;
KNOX, RM ;
MARTINEZMAZA, O .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) :1038-1043
[3]  
Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO
[4]  
2-R
[5]   HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH [J].
BUSSOLINO, F ;
DIRENZO, MF ;
ZICHE, M ;
BOCCHIETTO, E ;
OLIVERO, M ;
NALDINI, L ;
GAUDINO, G ;
TAMAGNONE, L ;
COFFER, A ;
COMOGLIO, PM .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :629-641
[6]  
Chen Z, 1999, CLIN CANCER RES, V5, P1369
[7]   Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer [J].
Chopra, V ;
Dinh, TV ;
Hannigan, EV .
CANCER INVESTIGATION, 1998, 16 (03) :152-159
[8]   Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer [J].
Chopra, V ;
Dinh, TV ;
Hannigan, EV .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1997, 123 (03) :167-172
[9]  
De Vita F, 1998, ONCOL REP, V5, P649
[10]  
Dong G, 1997, J CELL BIOCHEM, P90